GENEVA — Antimicrobial resistance is continuing to threaten routine healthcare worldwide, with approximately one in six laboratory-confirmed bacterial infections found to be resistant to antibiotics in 2023, according to new data released by the World Health Organization (WHO).

The latest findings show that more governments have developed plans to tackle antimicrobial resistance (AMR), but major weaknesses in diagnostic testing, funding and implementation mean that many patients still cannot reliably obtain the right treatment at the right time.

AMR occurs when bacteria, viruses, fungi or parasites change over time and no longer respond adequately to medicines. This report focuses on the bacterial resistance data. When antibiotics lose effectiveness, infections can become harder to treat, increasing the risks associated with surgery, childbirth, cancer care and other routine medical procedures.

More National Plans, But Limited Implementation

WHO’s 2026 Tracking Antimicrobial Resistance Country Self-assessment Survey found that 173 countries reported having developed national plans to address AMR, more than double the 79 countries reporting plans in 2017. The survey was completed by 183 countries, representing 94% of WHO Member States.

However, only 22% of countries said they had both the necessary funding and full implementation of their national action plans. WHO says the gap between policy commitments and practical delivery leaves weaknesses across infection prevention, surveillance, diagnosis and access to effective medicines.

Diagnostic Capacity Remains A Major Weakness

Only 36% of countries reported having a national reference laboratory equipped to test the selected bacteria and fungi, well below the global target of 80% by 2030. Without reliable laboratory testing, clinicians may have difficulty identifying the organism causing an infection and determining which medicines are likely to work.

WHO also reported that 63% of countries had guidelines for appropriate antimicrobial use, while only slightly more than half reported surveillance systems capable of monitoring national antibiotic use and tracking resistance levels.

Weak testing systems can contribute to unnecessary antibiotic prescriptions or treatment with medicines that are ineffective against a resistant infection. They can also allow resistant infections and outbreaks to go undetected, limiting the information public-health authorities need to respond.

What Needs To Change

WHO is calling on governments to finance and implement their national AMR plans, strengthen infection prevention, expand laboratory capacity and improve access to quality-assured diagnostics and essential medicines. The organization has also released practical tools to help countries prioritize diagnostic tests for bacterial and fungal infections and resistance.

Prevention remains central. Vaccination, clean water, sanitation, hand hygiene, safe food production and strong infection-control practices can reduce the number of infections and, in turn, the need for antimicrobial medicines. Responsible prescribing and appropriate use in human health, animal health and agriculture are also important parts of the response.

For patients, the message is not to avoid prescribed antibiotics, but to use them only when advised by a qualified health professional and exactly as directed. Antibiotics do not treat viral illnesses such as the common cold or flu. Patients should not share leftover medicines or self-medicate with antibiotics.

WHO’s findings highlight a growing global priority: national strategies must translate into accessible testing and effective treatment in everyday healthcare settings, not remain only on paper.

Source: World Health Organization — More Countries Have AMR Plans, But Patients Still Lack Testing And Treatment.